Close this search box.

Seventeen Minutes of Science: Designing “Better” Babies: We Can Do It, But Should We?

Tune in weekly to our virtual series “Seventeen Minutes of Science” every Tuesday at 11am PST / 2pm ET where we go live on Facebook with a new guest each week to talk about how science and biotechnology is woven into their lives for (you guessed it) 17 minutes!

This week on 17 Minutes of Science: Designing “Better” Babies: We Can Do It…But Should We?

“Designer babies” have become a hot topic over the past few years, but to anyone who is familiar with CRISPR/Cas9 genome editing (or even those who have seen the 1997 film Gattaca) the concept of genetically modified babies is not a new one. In fact, the technology has been around for quite awhile. So why are “designer babies” making headlines now, what are they, and why are scientists so concerned? Tune in this week as we discuss with Güneş Taylor about the subject.

Güneş Taylor is a Postdoctoral Training Fellow in the Lovell-Badge Lab at the Francis Crick Institute of London. The lab’s work revolves around Stem Cell Biology and Developmental Genetics, and she’s specifically looking at methods of sex-determination during development. Güneş has spoken many times on the subject of “designer babies” and will be sharing her views and ideas with us during this week’s episode. Güneş is also a mental health first aider through her work and believes the two go hand in hand.

Tune in to watch the interview and learn more about the interesting subject of CRISPR and designer babies!

About The Author

InVivo Biosystems

InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.

Share this articles

Picture of InVivo Biosystems

About the Author:

Connect with us